Novartis announced significant progress in treating Sjögren's syndrome with its B-cell-targeting antibody ianalumab. The drug met primary endpoints in two late-stage Phase 3 trials, marking the first global demonstration of statistically significant disease activity reduction for this chronic autoimmune condition. Data indicate favorable safety and sustained benefit, positioning ianalumab as a promising candidate to address a disease with limited therapeutic options. The company plans to engage regulators soon to pursue approval. This advancement follows Novartis’ discontinuation of a competing asset, consolidating their autoimmune pipeline around ianalumab.